Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shervin Assassi

Showing results (191-200 of 238) with videos related to

Pageof 24
Sort By:
The Journal of Clinical Investigation|March 5, 2019
Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylationTingting Weng, Junsuk Ko, Chioniso P Masamha, et al.
ACR Open Rheumatology|March 30, 2022
47XXY and 47XXX in Scleroderma and MyositisR Hal Scofield, Valerie M Lewis, Joshua Cavitt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
RMD Open|August 13, 2025
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypesJavier Martínez-López, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Annals of the Rheumatic Diseases|May 30, 2026
Novel HLA class I and II insights into the pathogenesis of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Pageof 24

Showing results (191-200 of 238) with videos related to

Sort By:
Pageof 24
The Journal of Clinical Investigation|March 5, 2019
Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylationTingting Weng, Junsuk Ko, Chioniso P Masamha, et al.
ACR Open Rheumatology|March 30, 2022
47XXY and 47XXX in Scleroderma and MyositisR Hal Scofield, Valerie M Lewis, Joshua Cavitt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
RMD Open|August 13, 2025
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypesJavier Martínez-López, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Annals of the Rheumatic Diseases|May 30, 2026
Novel HLA class I and II insights into the pathogenesis of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Pageof 24